Proteonomix, Inc. (PROT)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Jun 2, 2025

Proteonomix Company Description

Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives.

The company’s products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue.

Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles.

The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008.

Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.

Proteonomix, Inc.
Country United States
Founded 1995
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Michael Cohen

Contact Details

Address:
145 Highview Terrace
Hawthorne, Delaware 07506
United States
Phone 973-949-4193
Website proteonomix.com

Stock Details

Ticker Symbol PROT
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US74371C2089
SIC Code 2836

Key Executives

Name Position
Michael Cohen Founder, Chairman, Chief Executive Officer, President and Chief Operating Officer
Steven Byle Chief Technology Officer and Director